China Resources Pharmaceutical Group Ltd
HKEX:3320
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
HK |
Multiples-Based Value
The Multiples-Based Value of one China Resources Pharmaceutical Group Ltd stock under the Base Case scenario is 17.12 HKD. Compared to the current market price of 5.64 HKD, China Resources Pharmaceutical Group Ltd is Undervalued by 67%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
China Resources Pharmaceutical Group Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| HK |
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
35.4B HKD | 0.1 | 8.5 | 0.9 | 1.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.9 | 40.6 | 27.4 | 29.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 20.3 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.5 | 17.1 | 7.2 | 8.9 |